Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 12/20 | 0.51 |
| ▸ | PTPRC | P08575 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6941175 | 0.92 | PTPN1 (0.59) | PTPN1PTPRC | |
| SCHEMBL7886828 | 0.88 | PTPN1 (0.55) | PTPN1PTPRC | |
| SCHEMBL6946475 | 0.85 | PTPN1 (0.52) | PTPN1PTPRC | |
| SCHEMBL6946462 | 0.83 | PTPN1 (0.73) | PTPN1PTPRC | |
| SCHEMBL7886821 | 0.75 | PTPN1 (0.70) | PTPN1PTPRC | |
| SCHEMBL6941229 | 0.75 | PTPN1 (0.41) | PTPN1PTPRC | |
| SCHEMBL7886900 | 0.74 | PTPN1 (0.51) | PTPN1PTPRCEPHX2NR1H4 | |
| SCHEMBL7592325 | 0.74 | PTPN1 (0.50) | PTPN1PTPRCEPHX2 | |
| SCHEMBL6948682 | 0.73 | PTPN1 (0.63) | PTPN1PTPRC | |
| SCHEMBL6946538 | 0.73 | PTPN1 (0.55) | PTPN1PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1115729-B1 | PHOSPHONIC ACID DERIVATIVES AS INHIBITORS OF PTP-1B | MERCK FROSST CANADA INC (CA) | 2003-02-19 | — | — | EP | disclosed |
| US-6174874-B1 | ANTIDIABETIC,-CARCINOGENIC AGENTS; IMPROVING GLUCOSE TOLERANCE/INSULIN-SENSITIVITY; PREVENTING/TREATING OBESITY AND NEURODEGENERATIVE DISEASES; E.G. 1,3-BIS-((PHOSPHONODI-FLUOROMETHYL)PHENYL)-2-DICARBOXYPROPANE | MERCK FROSST CANADA & CO. (CA) | 2001-01-16 | — | — | US | disclosed |